Centrient Pharmaceuticals
Atul Mishra is a seasoned quality management professional with extensive experience in the pharmaceutical industry, currently serving as Site Quality Head at Centrient Pharmaceuticals since July 2025, overseeing quality management for two manufacturing sites with a focus on GMP compliance and operational excellence. Prior to this role, Atul spent over 14 years at Teva Active Pharmaceutical Ingredients, holding various leadership positions including Director of Site Quality and Global Compliance, where responsibilities included managing Japan quality compliance and global quality strategy across multiple regions. Atul began a career in quality assurance with roles that emphasized the implementation of quality systems and cGMP compliance, and is equipped with a Bachelor of Engineering in Chemical Engineering and a Diploma in Cement Technology.
This person is not in any teams
This person is not in any offices
Centrient Pharmaceuticals
2 followers
Centrient Pharmaceuticals is the global business-to-business leader in sustainable, enzymatic antibiotics, next generation statins and anti-fungals. We produce and sell intermediates and active pharmaceutical ingredients (APIs), as well as our own tablets, capsules and other finished dosage forms (FDFs). We stand proudly at the centre of modern healthcare, as a maker of essential and life-saving medicines. With our commitment to Quality, Reliability and Sustainability at the heart of everything we do, our over 1,800 employees work continuously to meet our customers’ needs. We work towards a sustainable future by actively participating in the fight against antimicrobial resistance. Founded 150 years ago as the ‘Nederlandsche Gist- en Spiritusfabriek’, our company was known as Gist Brocades and more recently DSM Sinochem Pharmaceuticals. Headquartered in Rotterdam (Netherlands), we have production facilities and sales offices in China, India, the Netherlands, Spain, the United States and Mexico. Centrient Pharmaceuticals is owned by Bain Capital Private Equity, a leading global private investment firm.